Dickkopf-1

Mechanism of Action

• Binds LRP5/6 third beta-propeller domain via C-terminal cysteine-rich domain-2 (CRD2), sterically blocking Wnt ligand from forming Frizzled-LRP5/6 ternary complex
• DKK1-LRP5/6 complex is internalized with Kremen1/2, reducing surface LRP5/6 levels and amplifying anti-Wnt effect
• In bone: DKK1 from osteoblasts suppresses osteoblast differentiation in negative feedback; DKK1 excess from tumor cells drives osteolytic lesions
• In cancer: DKK1 inhibits anti-tumor immune surveillance by suppressing Wnt-driven NK cell and CTL activation; DKK1 blockade restores immune cell function
• Embryonic: DKK1 from organizer region antagonizes Wnt at anterior end, allowing head structures to form by preventing caudalizing Wnt signals

Research Findings

• DKK1 knockout mice die perinatally with severe cranial and limb defects; heterozygous knockouts have increased bone density
• Multiple myeloma cells secrete high DKK1, suppressing osteoblast activity and driving osteolytic bone disease; anti-DKK1 antibodies restore bone formation in myeloma models
• BHQ880 (anti-DKK1 antibody): Phase II clinical trial in smoldering myeloma improved bone density vs zoledronic acid alone
• DKK1 serum levels correlate with osteolytic lesion burden in myeloma, Ewing sarcoma, and breast cancer bone metastases
• Anti-DKK1 immunotherapy combined with PD-1 blockade enhanced anti-tumor CD8+ T cell responses in preclinical solid tumor models

Research Protocols

• Recombinant DKK1: 1-100 nM to suppress Wnt3a-stimulated osteoblast differentiation; IC50 ~2-10 nM
• Myeloma bone disease model: 5T2MM myeloma cells + DKK1 neutralization with 100 mg/kg IP anti-DKK1 antibody weekly in C57Bl/KaLwRij mice
• Tumor immunology: DKK1-knockout tumor cells implanted in syngeneic mice; NK cell and CTL activity assessment by ELISPOT
• LRP6 binding assay: recombinant DKK1 displacement of Wnt3a from LRP6 ectodomain at 0.1-100 nM

Interactions

• Sclerostin: both inhibit LRP5/6 but bind different beta-propeller domains; cooperative suppression of bone Wnt signaling
• Kremen1 and Kremen2: DKK1 forms ternary complexes with Kremen and LRP5/6, driving LRP endocytosis and amplifying DKK1 effect
• Anti-DKK1 antibodies (BHQ880, DKN-01): clinical-stage therapeutics for myeloma and advanced cancers

Safety Profile

Recombinant DKK1 is a research tool. Anti-DKK1 antibody therapy: generally well tolerated in Phase I/II trials. Theoretical concern is anabolic bone effects causing hypercalcemia at high doses; not observed clinically at tested doses.

Legal & Regulatory

DKK1 itself is a research reagent. Anti-DKK1 antibodies (DKN-01) in Phase II clinical trials for esophageal and endometrial cancers.